메뉴 건너뛰기




Volumn 1045, Issue , 2013, Pages 1-27

Antibody-drug conjugate (ADC) clinical pipeline: A review

Author keywords

Antibody; Antibody drug conjugate; Auristatin; Calicheamicin; Cancer; CMC 544; Cytotoxic; Linker; Maytansine; SGN 35; T DM1

Indexed keywords

AGS 16M 8F; AGS 22M 6E; AGS 5M 2E; AGS 6MF; AMG 172; AMG 595; ANTIBODY CONJUGATE; ANTIBODY DRUG CONJUGATE; ANTINEOPLASTIC AGENT; ASG 22ME; ASG 5ME; AVE 9633; BAY 79 4620; BAY 94 9343; BIIB 015; BRENTUXIMAB VEDOTIN; BT 062; CANTUZUMAB RAVTANSINE; CMB 401; CMD 193; DCDS 4501A; DCDT 2980S; DEDN 6526A; DOXORUBICIN; DRUG ANTIBODY; DSTP 3086S; GEMTUZUMAB OZOGAMICIN; GLEMBATUMUMAB VEDOTIN; HUDS 6DM 4; IMGN 388; IMGN 529; IMMU 110; IMMU 130; INOTUZUMAB OZOGAMICIN; LORVOTUZUMAB MERTANSINE; MDX 1203; MEDI 547; MILATUZUMAB; MLN 2704; MONOCLONAL ANTIBODY; PSMA ADC; PSMA ADC 1301; RG 7450; RG 7458; RG 7593; RG 7596; RG 7598; RG 7599; RG 7600; SAR 3419; SAR 566658; SGN 15; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG;

EID: 84934444640     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-541-5_1     Document Type: Review
Times cited : (136)

References (125)
  • 1
    • 84860896956 scopus 로고    scopus 로고
    • Marketed therapeutic antibodies compendium
    • Reichert JM (2012) Marketed therapeutic antibodies compendium. MAbs 4:413-415
    • (2012) MAbs , vol.4 , pp. 413-415
    • Reichert, J.M.1
  • 2
    • 25144485908 scopus 로고    scopus 로고
    • Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence
    • Larson RA, Sievers EL, Stadtmauer EA et al (2005) Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104:1442-1452
    • (2005) Cancer , vol.104 , pp. 1442-1452
    • Larson, R.A.1    Sievers, E.L.2    Stadtmauer, E.A.3
  • 3
    • 0035397980 scopus 로고    scopus 로고
    • Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
    • Sievers EL, Larson RA, Stadtmauer EA et al (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol J Am Soc Clin Oncol 19:3244-3254
    • (2001) J Clin Oncol J Am Soc Clin Oncol , vol.19 , pp. 3244-3254
    • Sievers, E.L.1    Larson, R.A.2    Stadtmauer, E.A.3
  • 4
    • 80054113954 scopus 로고    scopus 로고
    • Antibody-drug conjugates of calicheamicin derivative: Gemtuzumab ozogamicin and inotuzumab ozogamicin
    • Ricart AD (2011) Antibody-drug conjugates of calicheamicin derivative: Gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res J Am Assoc Cancer Res 17:6417-6427
    • (2011) Clin Cancer Res J Am Assoc Cancer Res , vol.17 , pp. 6417-6427
    • Ricart, A.D.1
  • 5
    • 74849092615 scopus 로고    scopus 로고
    • Antibody-drug conjugate targets
    • Teicher BA (2009) Antibody-drug conjugate targets. Curr Cancer Drug Targets 9:982-1004
    • (2009) Curr Cancer Drug Targets , vol.9 , pp. 982-1004
    • Teicher, B.A.1
  • 6
    • 3042736089 scopus 로고    scopus 로고
    • A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors
    • Helft PR, Schilsky RL, Hoke FJ et al (2004) A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res J Am Assoc Cancer Res 10:4363-4368
    • (2004) Clin Cancer Res J Am Assoc Cancer Res , vol.10 , pp. 4363-4368
    • Helft, P.R.1    Schilsky, R.L.2    Hoke, F.J.3
  • 7
    • 0037440038 scopus 로고    scopus 로고
    • Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: A phase I, pharmacokinetic, and biologic correlative study
    • Tolcher AW, Ochoa L, Hammond LA et al (2003) Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: A phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol J Am Soc Clin Oncol 21:211-222
    • (2003) J Clin Oncol J Am Soc Clin Oncol , vol.21 , pp. 211-222
    • Tolcher, A.W.1    Ochoa, L.2    Hammond, L.A.3
  • 9
    • 50049134725 scopus 로고    scopus 로고
    • Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma
    • Riechelmann H, Sauter A, Golze W et al (2008) Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol 44:823-829
    • (2008) Oral Oncol , vol.44 , pp. 823-829
    • Riechelmann, H.1    Sauter, A.2    Golze, W.3
  • 10
    • 34247890107 scopus 로고    scopus 로고
    • Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck
    • Sauter A, Kloft C, Gronau S et al (2007) Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. Int J Oncol 30:927-935
    • (2007) Int J Oncol , vol.30 , pp. 927-935
    • Sauter, A.1    Kloft, C.2    Gronau, S.3
  • 11
    • 33750685640 scopus 로고    scopus 로고
    • A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus
    • Tijink BM, Buter J, Bree R et al (2006) A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res J Am Assoc Cancer Res 12:6064-6072
    • (2006) Clin Cancer Res J Am Assoc Cancer Res , vol.12 , pp. 6064-6072
    • Tijink, B.M.1    Buter, J.2    Bree, R.3
  • 12
    • 84862162222 scopus 로고    scopus 로고
    • Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia
    • Lapusan S, Vidriales MB, Thomas X et al (2012) Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest New Drugs 30:1121-1131
    • (2012) Invest New Drugs , vol.30 , pp. 1121-1131
    • Lapusan, S.1    Vidriales, M.B.2    Thomas, X.3
  • 13
    • 84873614573 scopus 로고    scopus 로고
    • Preclinical evaluationof ananti-CD33-maytansinoidimmunoconjugate, huMy9-6-DM4 (AVE9633) for the targeted therapy of acute myeloid leukemia
    • Abstract LB-287
    • Chari R, Xie H, Leece B (2005) Preclinical evaluationof ananti-CD33-maytansinoidimmunoconjugate, huMy9-6-DM4 (AVE9633) for the targeted therapy of acute myeloid leukemia.Am Assoc Cancer Res, Abstract LB-287
    • (2005) Am Assoc Cancer Res
    • Chari, R.1    Xie, H.2    Leece, B.3
  • 14
    • 38949192547 scopus 로고    scopus 로고
    • Targeted cancer therapy: Conferring specificity to cytotoxic drugs
    • Chari RV (2008) Targeted cancer therapy: Conferring specificity to cytotoxic drugs. Acc Chem Res 41:98-107
    • (2008) Acc Chem Res , vol.41 , pp. 98-107
    • Chari, R.V.1
  • 15
    • 34447520330 scopus 로고    scopus 로고
    • Anticancer carrier-linked prodrugs in clinical trials
    • Kratz F, Ajaj KA, Warnecke A (2007) Anticancer carrier-linked prodrugs in clinical trials. Expert Opin Investig Drugs 16:1037-1058
    • (2007) Expert Opin Investig Drugs , vol.16 , pp. 1037-1058
    • Kratz, F.1    Ajaj, K.A.2    Warnecke, A.3
  • 16
    • 67649886201 scopus 로고    scopus 로고
    • Potent antibody drug conjugates for cancer therapy
    • Senter PD (2009) Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 13:235-244
    • (2009) Curr Opin Chem Biol , vol.13 , pp. 235-244
    • Senter, P.D.1
  • 17
    • 0026593928 scopus 로고
    • Immunoconjugates containing novel maytansinoids: Promising anticancer drugs
    • Chari RV, Martell BA, Gross JL et al (1992) Immunoconjugates containing novel maytansinoids: Promising anticancer drugs. Cancer Res 52:127-131
    • (1992) Cancer Res , vol.52 , pp. 127-131
    • Chari, R.V.1    Martell, B.A.2    Gross, J.L.3
  • 18
    • 33745847797 scopus 로고    scopus 로고
    • Semisynthetic maytansine analogues for the targeted treatment of cancer
    • Widdison WC, Wilhelm SD, Cavanagh EE et al (2006) Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 49:4392-4408
    • (2006) J Med Chem , vol.49 , pp. 4392-4408
    • Widdison, W.C.1    Wilhelm, S.D.2    Cavanagh, E.E.3
  • 19
    • 31544441685 scopus 로고    scopus 로고
    • Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity
    • Doronina SO, Mendelsohn BA, Bovee TD et al (2006) Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity. Bioconjug Chem 17:114-124
    • (2006) Bioconjug Chem , vol.17 , pp. 114-124
    • Doronina, S.O.1    Mendelsohn, B.A.2    Bovee, T.D.3
  • 20
    • 0036007598 scopus 로고    scopus 로고
    • An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia
    • Hamann PR, Hinman LM, Beyer CF et al (2002) An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug Chem 13:40-46
    • (2002) Choice of linker. Bioconjug Chem , vol.13 , pp. 40-46
    • Hamann, P.R.1    Hinman, L.M.2    Beyer, C.F.3
  • 21
    • 65549140215 scopus 로고    scopus 로고
    • Novel analogues of CC-1065 and the duocarmycins for the use in targeted tumour therapies
    • Tietze LF, Krewer B (2009) Novel analogues of CC-1065 and the duocarmycins for the use in targeted tumour therapies. Anticancer Agent Med Chem 9:304-325
    • (2009) Anticancer Agent Med Chem , vol.9 , pp. 304-325
    • Tietze, L.F.1    Krewer, B.2
  • 22
    • 74949107560 scopus 로고    scopus 로고
    • Antibody-drug conjugates: Linking cytotoxic payloads to monoclonal antibodies
    • Ducry L, Stump B (2010) Antibody-drug conjugates: Linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem 21:5-13
    • (2010) Bioconjug Chem , vol.21 , pp. 5-13
    • Ducry, L.1    Stump, B.2
  • 24
    • 10744222473 scopus 로고    scopus 로고
    • Development of potent monoclonal antibody auristatin conjugates for cancer therapy
    • Doronina SO, Toki BE, Torgov MY et al (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21:778-784
    • (2003) Nat Biotechnol , vol.21 , pp. 778-784
    • Doronina, S.O.1    Toki, B.E.2    Torgov, M.Y.3
  • 25
    • 74949139946 scopus 로고    scopus 로고
    • Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates
    • Erickson HK, Widdison WC, Mayo MF et al (2010) Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem 21:84-92
    • (2010) Bioconjug Chem , vol.21 , pp. 84-92
    • Erickson, H.K.1    Widdison, W.C.2    Mayo, M.F.3
  • 26
    • 79955022475 scopus 로고    scopus 로고
    • Disulfide-linked antibody-maytansinoid conjugates: Optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage
    • Kellogg BA, Garrett L, Kovtun Y et al (2011) Disulfide-linked antibody-maytansinoid conjugates: Optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjug Chem 22:717-727
    • (2011) Bioconjug Chem , vol.22 , pp. 717-727
    • Kellogg, B.A.1    Garrett, L.2    Kovtun, Y.3
  • 27
    • 76049122850 scopus 로고    scopus 로고
    • Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate
    • Okeley NM, Miyamoto JB, Zhang X et al (2010) Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res J Am Assoc Cancer Res 16:888-897
    • (2010) Clin Cancer Res J Am Assoc Cancer Res , vol.16 , pp. 888-897
    • Okeley, N.M.1    Miyamoto, J.B.2    Zhang, X.3
  • 28
    • 33644787435 scopus 로고    scopus 로고
    • Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen
    • Kovtun YV, Audette CA, Ye Y et al (2006) Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 66:3214-3221
    • (2006) Cancer Res , vol.66 , pp. 3214-3221
    • Kovtun, Y.V.1    Audette, C.A.2    Ye, Y.3
  • 29
    • 12244295755 scopus 로고    scopus 로고
    • In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate
    • Sanderson RJ, Hering MA, James SF et al (2005) In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res J Am Assoc Cancer Res 11:843-852
    • (2005) Clin Cancer Res J Am Assoc Cancer Res , vol.11 , pp. 843-852
    • Sanderson, R.J.1    Hering, M.A.2    James, S.F.3
  • 30
    • 6044223544 scopus 로고    scopus 로고
    • Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate
    • Hamblett KJ, Senter PD, Chace DF et al (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res J Am Assoc Cancer Res 10:7063-7070
    • (2004) Clin Cancer Res J Am Assoc Cancer Res , vol.10 , pp. 7063-7070
    • Hamblett, K.J.1    Senter, P.D.2    Chace, D.F.3
  • 31
    • 84863012529 scopus 로고    scopus 로고
    • Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
    • Shen B, Xu K, Liu L et al (2012) Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 30:184-189
    • (2012) Nat Biotechnol , vol.30 , pp. 184-189
    • Shen, B.1    Xu, K.2    Liu, L.3
  • 32
    • 79952718320 scopus 로고    scopus 로고
    • Analytical methods for physicochemical characterization of antibody drug conjugates
    • Wakankar A, Chen Y, Gokarn Y et al (2011) Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs 3:161-172
    • (2011) MAbs , vol.3 , pp. 161-172
    • Wakankar, A.1    Chen, Y.2    Gokarn, Y.3
  • 33
    • 80052076003 scopus 로고    scopus 로고
    • CD30: An important new target in hematologic malignancies
    • Deutsch YE, Tadmor T, Podack ER et al (2011) CD30: An important new target in hematologic malignancies. Leuk Lymphoma 52:1641-1654
    • (2011) Leuk Lymphoma , vol.52 , pp. 1641-1654
    • Deutsch, Y.E.1    Tadmor, T.2    Podack, E.R.3
  • 34
    • 77950099811 scopus 로고    scopus 로고
    • Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma
    • Gerber H (2010) Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma. Biochem Pharmacol 79:1544-1552
    • (2010) Biochem Pharmacol , vol.79 , pp. 1544-1552
    • Gerber, H.1
  • 36
    • 80054111050 scopus 로고    scopus 로고
    • CD30-targeted antibody therapy
    • Younes A (2011) CD30-targeted antibody therapy. Curr Opin Oncol 23:587-593
    • (2011) Curr Opin Oncol , vol.23 , pp. 587-593
    • Younes, A.1
  • 37
    • 84856998215 scopus 로고    scopus 로고
    • Emerging pharmacotherapy for relapsed or refractory Hodgkin's lymphoma: Focus on brentuximab vedotin
    • Furtado M, Rule S (2012) Emerging pharmacotherapy for relapsed or refractory Hodgkin's lymphoma: Focus on brentuximab vedotin. Clin Med Insight Oncol 6:31-39
    • (2012) Clin Med Insight Oncol , vol.6 , pp. 31-39
    • Furtado, M.1    Rule, S.2
  • 38
    • 84863678237 scopus 로고    scopus 로고
    • Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study
    • Pro B, Advani R, Brice P et al (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study. J Clin Oncol J Am Soc Clin Oncol 30:2190-2196
    • (2012) J Clin Oncol J Am Soc Clin Oncol , vol.30 , pp. 2190-2196
    • Pro, B.1    Advani, R.2    Brice, P.3
  • 39
    • 84863688504 scopus 로고    scopus 로고
    • The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
    • Senter PD, Sievers EL (2012) The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 30:631-637
    • (2012) Nat Biotechnol , vol.30 , pp. 631-637
    • Senter, P.D.1    Sievers, E.L.2
  • 40
    • 0042738861 scopus 로고    scopus 로고
    • Cac10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity
    • Francisco JA, Cerveny CG, Meyer DL et al (2003) cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102:1458-1465
    • (2003) Blood , vol.102 , pp. 1458-1465
    • Francisco, J.A.1    Cerveny, C.G.2    Meyer, D.L.3
  • 41
    • 78049515807 scopus 로고    scopus 로고
    • Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas
    • Younes A, Bartlett NL, Leonard JP et al (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812-1821
    • (2010) N Engl J Med , vol.363 , pp. 1812-1821
    • Younes, A.1    Bartlett, N.L.2    Leonard, J.P.3
  • 42
    • 84855465227 scopus 로고    scopus 로고
    • A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies
    • Fanale MA, Forero-Torres A, Rosenblatt JD et al (2012) A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res J Am Assoc Cancer Res 18:248-255
    • (2012) Clin Cancer Res J Am Assoc Cancer Res , vol.18 , pp. 248-255
    • Fanale, M.A.1    Forero-Torres, A.2    Rosenblatt, J.D.3
  • 43
    • 84863676500 scopus 로고    scopus 로고
    • Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin and other lymphoma
    • Younes A, Gopal AK, Smith SE et al (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin and other lymphoma. J Clin Oncol J Am Soc Clin Oncol 30:2183-2189
    • (2012) J Clin Oncol J Am Soc Clin Oncol , vol.30 , pp. 2183-2189
    • Younes, A.1    Gopal, A.K.2    Smith, S.E.3
  • 44
    • 84858032909 scopus 로고    scopus 로고
    • Brentuximab vedotin: A new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma
    • Minich SS (2012) Brentuximab vedotin: A new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma. Ann Pharmacother 46:377-383
    • (2012) Ann Pharmacother , vol.46 , pp. 377-383
    • Minich, S.S.1
  • 45
    • 0028670125 scopus 로고
    • The biology of erbB-2/neu/HER-2 and its role in cancer
    • Hynes NE, Stern DF (1994) The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198:165-184
    • (1994) Biochim Biophys Acta , vol.1198 , pp. 165-184
    • Hynes, N.E.1    Stern, D.F.2
  • 46
    • 73949090721 scopus 로고    scopus 로고
    • Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review
    • Dawood S, Broglio K, Buzdar AU et al (2010) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review. J Clin Oncol J Am Soc Clin Oncol 28:92-98
    • (2010) J Clin Oncol J Am Soc Clin Oncol , vol.28 , pp. 92-98
    • Dawood, S.1    Broglio, K.2    Buzdar, A.U.3
  • 47
    • 84655162706 scopus 로고    scopus 로고
    • Treatment of HER2-positive breast cancer: Current status and future perspectives
    • Arteaga CL, Sliwkowski MX, Osborne CK et al (2012) Treatment of HER2-positive breast cancer: Current status and future perspectives. Nat Rev Clin Oncol 9:16-32
    • (2012) Nat Rev Clin Oncol , vol.9 , pp. 16-32
    • Arteaga, C.L.1    Sliwkowski, M.X.2    Osborne, C.K.3
  • 48
    • 84855406013 scopus 로고    scopus 로고
    • Beyond trastuzumab: Novel therapeutic strategies in HER2-positive metastatic breast cancer
    • Tsang RY, Finn RS (2012) Beyond trastuzumab: Novel therapeutic strategies in HER2-positive metastatic breast cancer. Br J Cancer 106:6-13
    • (2012) Br J Cancer , vol.106 , pp. 6-13
    • Tsang, R.Y.1    Finn, R.S.2
  • 49
    • 56449129810 scopus 로고    scopus 로고
    • Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate
    • Phillips GD, Li G, Dugger DL et al (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68:9280-9290
    • (2008) Cancer Res , vol.68 , pp. 9280-9290
    • Phillips, G.D.1    Li, G.2    Dugger, D.L.3
  • 50
    • 79959700509 scopus 로고    scopus 로고
    • Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
    • Junttila TT, Li G, Parsons K et al (2011) Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 128:347-356
    • (2011) Breast Cancer Res Treat , vol.128 , pp. 347-356
    • Junttila, T.T.1    Li, G.2    Parsons, K.3
  • 51
    • 84860389569 scopus 로고    scopus 로고
    • Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo
    • Barok M, Tanner M, Koninki K et al (2011) Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res BCR 13:R46
    • (2011) Breast Cancer Res BCR , vol.13
    • Barok, M.1    Tanner, M.2    Koninki, K.3
  • 52
    • 77954031486 scopus 로고    scopus 로고
    • Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer
    • Krop IE, Beeram M, Modi S et al (2010) Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol J Am Soc Clin Oncol 28:2698-2704
    • (2010) J Clin Oncol J Am Soc Clin Oncol , vol.28 , pp. 2698-2704
    • Krop, I.E.1    Beeram, M.2    Modi, S.3
  • 53
    • 84869508508 scopus 로고    scopus 로고
    • A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer
    • Beeram M, Krop IE, Burris HA et al (2012) A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. Cancer 118:5733-5740
    • (2012) Cancer , vol.118 , pp. 5733-5740
    • Beeram, M.1    Krop, I.E.2    Burris, H.A.3
  • 54
    • 80054989315 scopus 로고    scopus 로고
    • Trastuzumab emtansine (T-DM1): A novel agent for targeting HER2+ breast cancer
    • Burris HA, Tibbitts J, Holden SN et al (2011) Trastuzumab emtansine (T-DM1): A novel agent for targeting HER2+ breast cancer. Clin Breast Cancer 11:275-282
    • (2011) Clin Breast Cancer , vol.11 , pp. 275-282
    • Burris, H.A.1    Tibbitts, J.2    Holden, S.N.3
  • 55
    • 80054109854 scopus 로고    scopus 로고
    • Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: A review
    • Mathew J, Perez EA (2011) Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: A review. Curr Opin Oncol 23:594-600
    • (2011) Curr Opin Oncol , vol.23 , pp. 594-600
    • Mathew, J.1    Perez, E.A.2
  • 56
    • 80054092983 scopus 로고    scopus 로고
    • Trastuzumab emtansine: A unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer
    • Lorusso PM, Weiss D, Guardino E et al (2011) Trastuzumab emtansine: A unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res J Am Assoc Cancer Res 17:6437-6447
    • (2011) Clin Cancer Res J Am Assoc Cancer Res , vol.17 , pp. 6437-6447
    • Lorusso, P.M.1    Weiss, D.2    Guardino, E.3
  • 57
    • 79952092706 scopus 로고    scopus 로고
    • Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy
    • Burris HA, Rugo HS, Vukelja SJ et al (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol J Am Soc Clin Oncol 29:398-405
    • (2011) J Clin Oncol J Am Soc Clin Oncol , vol.29 , pp. 398-405
    • Burris, H.A.1    Rugo, H.S.2    Vukelja, S.J.3
  • 58
    • 84863688392 scopus 로고    scopus 로고
    • A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine
    • Krop IE, Lorusso P, Miller KD et al (2012) A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol J Am Soc Clin Oncol 30:3234-3241
    • (2012) J Clin Oncol J Am Soc Clin Oncol , vol.30 , pp. 3234-3241
    • Krop, I.E.1    Lorusso, P.2    Miller, K.D.3
  • 59
    • 84862228236 scopus 로고    scopus 로고
    • Clinical pharmacology of trastuzumab emtansine (T-DM1): An antibody-drug conjugate in development for the treatment of HER2-positive cancer
    • Girish S, Gupta M, Wang B et al (2012) Clinical pharmacology of trastuzumab emtansine (T-DM1): An antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol 69:1229-1240
    • (2012) Cancer Chemother Pharmacol , vol.69 , pp. 1229-1240
    • Girish, S.1    Gupta, M.2    Wang, B.3
  • 60
    • 84860307997 scopus 로고    scopus 로고
    • Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer
    • Gupta M, Lorusso PM, Wang B et al (2012) Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. J Clin Pharmacol 52:691-703
    • (2012) J Clin Pharmacol , vol.52 , pp. 691-703
    • Gupta, M.1    Lorusso, P.M.2    Wang, B.3
  • 61
    • 79551609265 scopus 로고    scopus 로고
    • Efficacy and safety of trastuzumab-DM1 versus trastuzumab plus docetaxel in HER2-positive metastatic breast cancer patients with no prior chemotherapy for metastatic disease: Preliminary results of a randomized, multicenter, open-label phase 2 study (TDM4450g
    • viii2, Abstract LBA3
    • Perez E, Dirix L, Kocsis J et al (2010) Efficacy and safety of trastuzumab-DM1 versus trastuzumab plus docetaxel in HER2-positive metastatic breast cancer patients with no prior chemotherapy for metastatic disease: Preliminary results of a randomized, multicenter, open-label phase 2 study (TDM4450g). Ann Oncol 21(Suppl 8):viii2, Abstract LBA3
    • (2010) Ann Oncol , vol.21 , Issue.SUPPL.8
    • Perez, E.1    Dirix, L.2    Kocsis, J.3
  • 62
    • 83255175479 scopus 로고    scopus 로고
    • Trastuzumab emtansine (T-DM1) vs trastuzumab plus docetaxel (H + T) in previouslyuntreated HER2-positive metastatic breast cancer (MBC): Primary results of a randomized, multicenter, open-label phase II study (TDM4450g/B021976
    • ECCO-ESMO, Abstract 5001
    • Hurvitz S, Dirix L, Kocsis J et al (2011) Trastuzumab emtansine (T-DM1) vs trastuzumab plus docetaxel (H + T) in previouslyuntreated HER2-positive metastatic breast cancer (MBC): Primary results of a randomized, multicenter, open-label phase II study (TDM4450g/B021976). Eur J Cancer 47:ECCO-ESMO, Abstract 5001
    • (2011) Eur J Cancer , vol.47
    • Hurvitz, S.1    Dirix, L.2    Kocsis, J.3
  • 63
    • 84868520609 scopus 로고    scopus 로고
    • Trastuzumab emtansine for HER2-positive advanced breast cancer
    • Verma S, Miles D, Gianni L et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783-1791
    • (2012) N Engl J Med , vol.367 , pp. 1783-1791
    • Verma, S.1    Miles, D.2    Gianni, L.3
  • 64
    • 26644450721 scopus 로고    scopus 로고
    • CD22: A multifunctional receptor that regulates B lymphocyte survival and signal transduction
    • Tedder TF, Poe JC, Haas KM (2005) CD22: A multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv Immunol 88:1-50
    • (2005) Adv Immunol , vol.88 , pp. 1-50
    • Tedder, T.F.1    Poe, J.C.2    Haas, K.M.3
  • 65
    • 0029025026 scopus 로고
    • Constitutive endocytosis and degradation of CD22 by human B cells
    • Shan D, Press OW (1995) Constitutive endocytosis and degradation of CD22 by human B cells. J Immunol 154:4466-4475
    • (1995) J Immunol , vol.154 , pp. 4466-4475
    • Shan, D.1    Press, O.W.2
  • 66
    • 77954681710 scopus 로고    scopus 로고
    • Inotuzumab ozogamicin as novel therapy in lymphomas
    • Wong BY, Dang NH (2010) Inotuzumab ozogamicin as novel therapy in lymphomas. Expert Opin Biol Ther 10:1251-1258
    • (2010) Expert Opin Biol Ther , vol.10 , pp. 1251-1258
    • Wong, B.Y.1    Dang, N.H.2
  • 67
    • 84861040649 scopus 로고    scopus 로고
    • Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia
    • Thomas X (2012) Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia. Expert Opin Investig Drugs 21:871-878
    • (2012) Expert Opin Investig Drugs , vol.21 , pp. 871-878
    • Thomas, X.1
  • 68
    • 4544320025 scopus 로고    scopus 로고
    • Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma
    • DiJoseph JF, Goad ME, Dougher MM et al (2004) Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin Cancer Res J Am Assoc Cancer Res 10:8620-8629
    • (2004) Clin Cancer Res J Am Assoc Cancer Res , vol.10 , pp. 8620-8629
    • DiJoseph, J.F.1    Goad, M.E.2    Dougher, M.M.3
  • 69
    • 77951648118 scopus 로고    scopus 로고
    • Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin and other lymphoma: Results of a phase I study
    • Advani A, Coiffier B, Czuczman MS et al (2010) Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin and other lymphoma: Results of a phase I study. J Clin Oncol J Am Soc Clin Oncol 28:2085-2093
    • (2010) J Clin Oncol J Am Soc Clin Oncol , vol.28 , pp. 2085-2093
    • Advani, A.1    Coiffier, B.2    Czuczman, M.S.3
  • 70
    • 77954839504 scopus 로고    scopus 로고
    • Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximabbased therapy
    • Ogura M, Tobinai K, Hatake K et al (2010) Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximabbased therapy. Cancer Sci 101:1840-1845
    • (2010) Cancer Sci , vol.101 , pp. 1840-1845
    • Ogura, M.1    Tobinai, K.2    Hatake, K.3
  • 71
    • 31544455876 scopus 로고    scopus 로고
    • Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma
    • DiJoseph JF, Dougher MM, Kalyandrug LB et al (2006) Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clin Cancer Res J Am Assoc Cancer Res 12:242-249
    • (2006) Clin Cancer Res J Am Assoc Cancer Res , vol.12 , pp. 242-249
    • DiJoseph, J.F.1    Dougher, M.M.2    Kalyandrug, L.B.3
  • 72
    • 77953682059 scopus 로고    scopus 로고
    • Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab: Clinical activity including survival in patients with recurrent/refractory follicular or "aggressive" lymphoma
    • Abstract 584
    • Dang N, Smith M, Offner F et al (2009) Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab: Clinical activity including survival in patients with recurrent/refractory follicular or "aggressive" lymphoma. Blood 114, Abstract 584
    • (2009) Blood , vol.114
    • Dang, N.1    Smith, M.2    Offner, F.3
  • 73
    • 67650873888 scopus 로고    scopus 로고
    • Safety and clinical activity of the anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) in combination with rituximab in follicular lymphoma or diffuse large B-cell lymphoma: Preliminary report of a phase 1/2 study
    • Abstract 266
    • Fayad L, Patel H, Verhoef G et al (2008) Safety and clinical activity of the anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) in combination with rituximab in follicular lymphoma or diffuse large B-cell lymphoma: Preliminary report of a phase 1/2 study. Blood 112, Abstract 266
    • (2008) Blood , vol.112
    • Fayad, L.1    Patel, H.2    Verhoef, G.3
  • 74
    • 80054122516 scopus 로고    scopus 로고
    • Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab: Clinical activity in patients with relapsed/refractory follicular or aggressive lymphomas
    • Abstract 0573
    • Verhoef G, Dang N, Smith M et al (2010) Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab: Clinical activity in patients with relapsed/refractory follicular or aggressive lymphomas. Haematologica 95, Abstract 0573
    • (2010) Haematologica , vol.95
    • Verhoef, G.1    Dang, N.2    Smith, M.3
  • 75
    • 80054113336 scopus 로고    scopus 로고
    • Inotuzumab ozogamicin (IO; CMC544), a CD22 monoclonal antibody attached to calicheamycin, produces complete response (CR) plus complete marrow response (mCR) of greater than 50% in refractory relapse (R-R) acute lymphocytic leukemia (ALL
    • Abstract 6507
    • Jabbour E, O'Brien S, Thomas DA, Ravandi F et al (2011) Inotuzumab ozogamicin (IO; CMC544), a CD22 monoclonal antibody attached to calicheamycin, produces complete response (CR) plus complete marrow response (mCR) of greater than 50% in refractory relapse (R-R) acute lymphocytic leukemia (ALL). J Clin Oncol 29, Abstract 6507
    • (2011) J Clin Oncol , vol.29
    • Jabbour, E.1    O'Brien, S.2    Thomas, D.A.3    Ravandi, F.4
  • 76
    • 84862786326 scopus 로고    scopus 로고
    • Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: A phase 2 study
    • Kantarjian H, Thomas D, Jorgensen J et al (2012) Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: A phase 2 study. Lancet Oncol 13:403-411
    • (2012) Lancet Oncol , vol.13 , pp. 403-411
    • Kantarjian, H.1    Thomas, D.2    Jorgensen, J.3
  • 77
    • 80054095609 scopus 로고    scopus 로고
    • SAR3419: An anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies
    • Blanc V, Bousseau A, Caron A et al (2011) SAR3419: An anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res J Am Assoc Cancer Res 17:6448-6458
    • (2011) Clin Cancer Res J Am Assoc Cancer Res , vol.17 , pp. 6448-6458
    • Blanc, V.1    Bousseau, A.2    Caron, A.3
  • 78
    • 84864544136 scopus 로고    scopus 로고
    • Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/ refractory B-cell lymphoma
    • Younes A, Kim S, Romaguera J et al (2012) Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/ refractory B-cell lymphoma. J Clin Oncol J Am Soc Clin Oncol 30:2776-2782
    • (2012) J Clin Oncol J Am Soc Clin Oncol , vol.30 , pp. 2776-2782
    • Younes, A.1    Kim, S.2    Romaguera, J.3
  • 79
    • 84866529248 scopus 로고    scopus 로고
    • Phase I study cohort evaluating an optimized administration schedule of SAR3419, an anti-CD19 DM4-loaded antibody drug conjugate (ADC), in patients (pts) with CD19 positive relapsed/refractory b-cell non-Hodgkin's lymphoma (NCT00796731
    • Abstract 8057
    • Coiffier B, Morschhauser F, Dupuis J et al (2012) Phase I study cohort evaluating an optimized administration schedule of SAR3419, an anti-CD19 DM4-loaded antibody drug conjugate (ADC), in patients (pts) with CD19 positive relapsed/refractory b-cell non-Hodgkin's lymphoma (NCT00796731). J Clin Oncol 30, Abstract 8057
    • (2012) J Clin Oncol , vol.30
    • Coiffier, B.1    Morschhauser, F.2    Dupuis, J.3
  • 80
    • 84866559756 scopus 로고    scopus 로고
    • CD19 as an attractive target for antibody-based therapy
    • Hammer O (2012) CD19 as an attractive target for antibody-based therapy. MAbs 4:571-577
    • (2012) MAbs , vol.4 , pp. 571-577
    • Hammer, O.1
  • 81
    • 84855702068 scopus 로고    scopus 로고
    • The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer
    • Keir CH, Vahdat LT (2012) The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer. Expert Opin Biol Ther 12:259-263
    • (2012) Expert Opin Biol Ther , vol.12 , pp. 259-263
    • Keir, C.H.1    Vahdat, L.T.2
  • 82
    • 33644747384 scopus 로고    scopus 로고
    • CR011, a fully human monoclonal antibody-Auristatin E conjugate, for the treatment of melanoma
    • Tse KF, Jeffers M, Pollack VA et al (2006) CR011, a fully human monoclonal antibody-Auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res J Am Assoc Cancer Res 12:1373-1382
    • (2006) Clin Cancer Res J Am Assoc Cancer Res , vol.12 , pp. 1373-1382
    • Tse, K.F.1    Jeffers, M.2    Pollack, V.A.3
  • 83
    • 77950835018 scopus 로고    scopus 로고
    • Glembatumumab vedotin, a conjugate of an antiglycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer
    • Naumovski L, Junutula JR (2010) Glembatumumab vedotin, a conjugate of an antiglycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer. Curr Opin Mol Ther 12:248-257
    • (2010) Curr Opin Mol Ther , vol.12 , pp. 248-257
    • Naumovski, L.1    Junutula, J.R.2
  • 84
    • 79952646477 scopus 로고    scopus 로고
    • Frequent dosing and GPNMB expression with CDX-011 (CR011-vcMMAE), an antibody-drug conjugate (ADC), in patients with advanced melanoma
    • Abstract 8525
    • Hamid O, Sznol M, Pavlick A et al (2010) Frequent dosing and GPNMB expression with CDX-011 (CR011-vcMMAE), an antibody-drug conjugate (ADC), in patients with advanced melanoma. J Clin Oncol 28, Abstract 8525
    • (2010) J Clin Oncol , vol.28
    • Hamid, O.1    Sznol, M.2    Pavlick, A.3
  • 85
    • 79952638233 scopus 로고    scopus 로고
    • Pharmacokinetics of CR011-vcMMAE, an antibody-drug conjugate, in a phase I study of patients with advanced melanoma
    • Abstract 9063
    • Szol M, Hamid O, Hwu P et al (2009) Pharmacokinetics of CR011-vcMMAE, an antibody-drug conjugate, in a phase I study of patients with advanced melanoma. J Clin Oncol 27, Abstract 9063
    • (2009) J Clin Oncol , vol.27
    • Szol, M.1    Hamid, O.2    Hwu, P.3
  • 86
    • 84858205260 scopus 로고    scopus 로고
    • Correlation of GPNMB expression with outcome in breast cancer (BC) patients treated with the antibody-drug conjugate (ADC), CDX-011 (CR011-vcMMAE
    • Abstract 1095
    • Saleh M, Bendell J, Rose et al (2010) Correlation of GPNMB expression with outcome in breast cancer (BC) patients treated with the antibody-drug conjugate (ADC), CDX-011 (CR011-vcMMAE). J Clin Oncol 28, Abstract 1095
    • (2010) J Clin Oncol , vol.28
    • Saleh, M.1    Bendell, J.2    Rose3
  • 87
    • 77952293797 scopus 로고    scopus 로고
    • Glycoprotein nonmetastatic melanoma protein b, a melanocytic cell marker, is a melanosome-specific and proteolytically released protein
    • Hoashi T, Sato S, Yamaguchi Y et al (2010) Glycoprotein nonmetastatic melanoma protein b, a melanocytic cell marker, is a melanosome-specific and proteolytically released protein. FASEB J 24:1616-1629
    • (2010) FASEB J , vol.24 , pp. 1616-1629
    • Hoashi, T.1    Sato, S.2    Yamaguchi, Y.3
  • 88
    • 80052665722 scopus 로고    scopus 로고
    • Prostate-specific membrane antigen-based therapeutics
    • Akhtar NH, Pail O, Saran A et al (2012) Prostate-specific membrane antigen-based therapeutics. Adv Urol 2012:973820
    • (2012) Adv Urol , vol.2012 , pp. 973820
    • Akhtar, N.H.1    Pail, O.2    Saran, A.3
  • 89
    • 3843113671 scopus 로고    scopus 로고
    • Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer
    • Ghosh A, Heston WD (2004) Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 91:528-539
    • (2004) J Cell Biochem , vol.91 , pp. 528-539
    • Ghosh, A.1    Heston, W.D.2
  • 90
    • 0033168844 scopus 로고    scopus 로고
    • Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-Associated neovasculature
    • Chang SS, Reuter VE, Heston WD et al (1999) Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-Associated neovasculature. Cancer Res 59:3192-3198
    • (1999) Cancer Res , vol.59 , pp. 3192-3198
    • Chang, S.S.1    Reuter, V.E.2    Heston, W.D.3
  • 91
    • 78951476072 scopus 로고    scopus 로고
    • High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer
    • Minner S, Wittmer C, Graefen M et al (2011) High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate 71:281-288
    • (2011) Prostate , vol.71 , pp. 281-288
    • Minner, S.1    Wittmer, C.2    Graefen, M.3
  • 92
    • 0031042591 scopus 로고    scopus 로고
    • Prostate-specific membrane antigen expression in normal and malignant human tissues
    • Silver DA, Pellicer I, Fair WR et al (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res J Am Assoc Cancer Res 3:81-85
    • (1997) Clin Cancer Res J Am Assoc Cancer Res , vol.3 , pp. 81-85
    • Silver, D.A.1    Pellicer, I.2    Fair, W.R.3
  • 93
    • 80052740269 scopus 로고    scopus 로고
    • In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatinconjugated antibody to prostate-specific membrane antigen
    • Wang X, Ma D, Olson WC et al (2011) In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatinconjugated antibody to prostate-specific membrane antigen. Mol Cancer Ther 10:1728-1739
    • (2011) Mol Cancer Ther , vol.10 , pp. 1728-1739
    • Wang, X.1    Ma, D.2    Olson, W.C.3
  • 94
    • 43749092340 scopus 로고    scopus 로고
    • Phase I trial of the prostatespecific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer
    • Galsky MD, Eisenberger M, Moore-Cooper S et al (2008) Phase I trial of the prostatespecific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol J Am Soc Clin Oncol 26:2147-2154
    • (2008) J Clin Oncol J Am Soc Clin Oncol , vol.26 , pp. 2147-2154
    • Galsky, M.D.1    Eisenberger, M.2    Moore-Cooper, S.3
  • 95
    • 84881571812 scopus 로고    scopus 로고
    • Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in men with prostate cancer previously treated with taxane
    • Abstract 107
    • Petrylak D, Kantoff P, Mega-A et al (2012) Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in men with prostate cancer previously treated with taxane. J Clin Oncol 30, Abstract 107
    • (2012) J Clin Oncol , vol.30
    • Petrylak, D.1    Kantoff, P.2    Mega, A.3
  • 96
    • 80052688423 scopus 로고    scopus 로고
    • Prostate-specific membrane antigen antibody-drug conjugate (PSMA ADC): A phase I trial in taxane-refractory prostate cancer
    • Abstract 4550
    • Petrylak D, Kantoff P, Frank R et al (2011) Prostate-specific membrane antigen antibody-drug conjugate (PSMA ADC): A phase I trial in taxane-refractory prostate cancer. J Clin Oncol 29, Abstract 4550
    • (2011) J Clin Oncol , vol.29
    • Petrylak, D.1    Kantoff, P.2    Frank, R.3
  • 97
    • 84934441487 scopus 로고    scopus 로고
    • Prostate specific membrane antigen antibody drug conjugate (PSMA ADC): A phase 1 trial in castration-resistant metastatic prostate cancer (mCRPC
    • Petrylak D, Kantoff P, Mega-A et al (2012) Prostate specific membrane antigen antibody drug conjugate (PSMA ADC): A phase 1 trial in castration-resistant metastatic prostate cancer (mCRPC). EORTC-NCI-AACR 47
    • (2012) EORTC-NCI-AACR , vol.47
    • Petrylak, D.1    Kantoff, P.2    Mega, A.3
  • 98
    • 8944235348 scopus 로고    scopus 로고
    • A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1
    • Wijdenes J, Vooijs WC, Clément C et al (1996) A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 94:318-323
    • (1996) Br J Haematol , vol.94 , pp. 318-323
    • Wijdenes, J.1    Vooijs, W.C.2    Clément, C.3
  • 99
    • 9444223279 scopus 로고    scopus 로고
    • Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells
    • Tassone P, Goldmacher VS, Neri P et al (2004) Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood 104:3688-3696
    • (2004) Blood , vol.104 , pp. 3688-3696
    • Tassone, P.1    Goldmacher, V.S.2    Neri, P.3
  • 100
    • 80054050580 scopus 로고    scopus 로고
    • BT062, an antibody-drug conjugate directed against CD138, shows clinical activity in a phase I study in patients with relapsed or relapsed/refractory multiple myeloma
    • Abstract 305
    • Jagannath S, Chanan-Khan A, Heffner L et al (2011) BT062, an antibody-drug conjugate directed against CD138, shows clinical activity in a phase I study in patients with relapsed or relapsed/refractory multiple myeloma. ASH Annual Meeting, Abstract 305
    • (2011) ASH Annual Meeting
    • Jagannath, S.1    Chanan-Khan, A.2    Heffner, L.3
  • 101
    • 77953663858 scopus 로고    scopus 로고
    • Antibody-maytansinoid conjugates for the treatment of myeloma
    • Lutz RJ, Whiteman KR (2009) Antibody-maytansinoid conjugates for the treatment of myeloma. MAbs 1:548-551
    • (2009) MAbs , vol.1 , pp. 548-551
    • Lutz, R.J.1    Whiteman, K.R.2
  • 102
    • 78650263326 scopus 로고    scopus 로고
    • Phase I study of IMGN901, used as monotherapy, in patients with heavily pretreated CD56-positive multiple myeloma -A preliminary safety and efficacy analysis
    • Abstract 2883
    • Chanan-Khan A, Wolf J, Gharibo M. et al (2009) Phase I study of IMGN901, used as monotherapy, in patients with heavily pretreated CD56-positive multiple myeloma -A preliminary safety and efficacy analysis. ASH Annual Meeting, Abstract 2883
    • (2009) ASH Annual Meeting
    • Chanan-Khan, A.1    Wolf, J.2    Gharibo, M.3
  • 103
    • 84908548836 scopus 로고    scopus 로고
    • Clinical experience of IMGN901 (BB-10901, huN901-DM1) in patients with Merkel cell carcinoma (MCC
    • Abstract B237
    • Woll P, Laurigan P, O'Brien M et al (2009) Clinical experience of IMGN901 (BB-10901, huN901-DM1) in patients with Merkel cell carcinoma (MCC). Mol Cancer Ther 8, Abstract B237
    • (2009) Mol Cancer Ther , vol.8
    • Woll, P.1    Laurigan, P.2    O'Brien, M.3
  • 104
    • 84857344699 scopus 로고    scopus 로고
    • Phase I study of lorvotuzumab mertansine (IMGN901) in patients with CD56-positive solid tumors
    • Abstract 536
    • Woll PJ, O'Brien M, Fossella F et al (2010) Phase I study of lorvotuzumab mertansine (IMGN901) in patients with CD56-positive solid tumors. Ann Oncol J Eur Soc Med Oncol ESMO, Abstract 536
    • (2010) Ann Oncol J Eur Soc Med Oncol ESMO
    • Woll, P.J.1    O'Brien, M.2    Fossella, F.3
  • 105
    • 79960248682 scopus 로고    scopus 로고
    • Phase I study of lorvotuzumab mertansine (IMGN901) used in combination with lenalidomide and dexamethasone in patients with CD56-positive multiple myeloma, a preliminary safety and efficacy analysis of the combination
    • Abstract. 1934
    • Berdeja J, Ailawadhi S, Niesvizky R et al (2010) Phase I study of lorvotuzumab mertansine (IMGN901) used in combination with lenalidomide and dexamethasone in patients with CD56-positive multiple myeloma, a preliminary safety and efficacy analysis of the combination. ASHAnnual Meeting, Abstract 1934
    • (2010) ASHAnnual Meeting
    • Berdeja, J.1    Ailawadhi, S.2    Niesvizky, R.3
  • 106
    • 84993814474 scopus 로고    scopus 로고
    • A single-Arm, open-label, multicenter phase I/ II study of the combination of panobinostat (pan) and carfilzomib (cfz) in patients (pts) with relapsed/refractory multiple myeloma (RR MM
    • Abstract TPS8115
    • Berdeja J, Mace J, Lamar R et al (2012) A single-Arm, open-label, multicenter phase I/ II study of the combination of panobinostat (pan) and carfilzomib (cfz) in patients (pts) with relapsed/refractory multiple myeloma (RR MM). J Clin Oncol 30, Abstract TPS8115
    • (2012) J Clin Oncol , vol.30
    • Berdeja, J.1    Mace, J.2    Lamar, R.3
  • 107
    • 84881587923 scopus 로고    scopus 로고
    • Early study on LGR5/GPR49 molecule as a potential colon cancer stem cell target for the antibody conjugated drug treatment
    • Abstract 4289
    • Mao W, Tien J, Goldenberg D et al (2010) Early study on LGR5/GPR49 molecule as a potential colon cancer stem cell target for the antibody conjugated drug treatment. Annual Meeting of the AACR, Abstract 4289
    • (2010) Annual Meeting of the AACR
    • Mao, W.1    Tien, J.2    Goldenberg, D.3
  • 108
  • 109
    • 84881598632 scopus 로고    scopus 로고
    • Ptk7 as a direct and tumor stroma target in multiple solid malignancies
    • Abstract 1526
    • Terrett J, Devasthali V, Pan C et al (2008) Ptk7 as a direct and tumor stroma target in multiple solid malignancies. Annual Meeting of the AACR, Abstract 1526
    • (2008) Annual Meeting of the AACR
    • Terrett, J.1    Devasthali, V.2    Pan, C.3
  • 110
    • 84934436644 scopus 로고    scopus 로고
    • Anti-tumor efficacy of the integrin-targeted immunoconjugate IMGN388 in preclinical models
    • Vater C, Manning C, Millar H et al (2008) Anti-tumor efficacy of the integrin-targeted immunoconjugate IMGN388 in preclinical models. EORTC-NCI-AACR, Abstract ENA-0399
    • (2008) EORTC-NCI-AACR, Abstract ENA-0399
    • Vater, C.1    Manning, C.2    Millar, H.3
  • 111
    • 84866241140 scopus 로고    scopus 로고
    • High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)-mediated inhibition of platelet production
    • Thon JN, Devine MT, Begonja AJ et al (2012) High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)-mediated inhibition of platelet production. Blood 120:1975-1984
    • (2012) Blood , vol.120 , pp. 1975-1984
    • Thon, J.N.1    Devine, M.T.2    Begonja, A.J.3
  • 112
    • 77950224905 scopus 로고    scopus 로고
    • Antibody-maytansinoid conjugates designed to bypass multidrug resistance
    • Kovtun YV, Audette CA, Mayo MF et al (2010) Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res 70:2528-2537
    • (2010) Cancer Res , vol.70 , pp. 2528-2537
    • Kovtun, Y.V.1    Audette, C.A.2    Mayo, M.F.3
  • 113
    • 84869137056 scopus 로고    scopus 로고
    • ADME of antibody-maytansinoid conjugates
    • Erickson HK, Lambert JM (2012) ADME of antibody-maytansinoid conjugates. AAPS J 14:799-805
    • (2012) AAPS J , vol.14 , pp. 799-805
    • Erickson, H.K.1    Lambert, J.M.2
  • 114
    • 84862752215 scopus 로고    scopus 로고
    • The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates
    • Erickson HK, Phillips GD, Leipold DD et al (2012) The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther 11:1133-1142
    • (2012) Mol Cancer Ther , vol.11 , pp. 1133-1142
    • Erickson, H.K.1    Phillips, G.D.2    Leipold, D.D.3
  • 115
    • 84866735537 scopus 로고    scopus 로고
    • Pharmacokinetic considerations for antibody drug conjugates
    • Lin K, Tibbitts J (2012) Pharmacokinetic considerations for antibody drug conjugates. Pharm Res 29:2354-2366
    • (2012) Pharm Res , vol.29 , pp. 2354-2366
    • Lin, K.1    Tibbitts, J.2
  • 116
    • 49449087300 scopus 로고    scopus 로고
    • Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
    • Junutula JR, Raab H, Clark S et al (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 26:925-932
    • (2008) Nat Biotechnol , vol.26 , pp. 925-932
    • Junutula, J.R.1    Raab, H.2    Clark, S.3
  • 117
    • 33745684533 scopus 로고    scopus 로고
    • Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment
    • McDonagh CF, Turcott E,Westendorf L et al (2006) Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng Design Select PEDS 19:299-307
    • (2006) Protein Eng Design Select PEDS , vol.19 , pp. 299-307
    • McDonagh, C.F.1    Turcott, E.2    Westendorf, L.3
  • 118
    • 79957730092 scopus 로고    scopus 로고
    • Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates
    • Zhao RY, Wilhelm SD, Audette C et al (2011) Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. J Med Chem 54:3606-3623
    • (2011) J Med Chem , vol.54 , pp. 3606-3623
    • Zhao, R.Y.1    Wilhelm, S.D.2    Audette, C.3
  • 119
    • 84860142832 scopus 로고    scopus 로고
    • Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma
    • Moldenhauer G, Salnikov AV, Luttgau AV et al (2012) Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. J Natl Cancer Inst 104:622-634
    • (2012) J Natl Cancer Inst , vol.104 , pp. 622-634
    • Moldenhauer, G.1    Salnikov, A.V.2    Luttgau, A.V.3
  • 120
    • 53349175018 scopus 로고    scopus 로고
    • Anti-CD30 diabody-drug conjugates with potent antitumor activity
    • Kim KM, McDonagh CF, Westendorf L et al (2008) Anti-CD30 diabody-drug conjugates with potent antitumor activity. Mol Cancer Ther 7:2486-2497
    • (2008) Mol Cancer Ther , vol.7 , pp. 2486-2497
    • Kim, K.M.1    McDonagh, C.F.2    Westendorf, L.3
  • 121
    • 84855577639 scopus 로고    scopus 로고
    • Practical theoretic guidance for the design of tumor-targeting agents
    • Wittrup KD, Thurber GM, SchmidtMMet al (2012) Practical theoretic guidance for the design of tumor-targeting agents. Methods Enzymol 503:255-268
    • (2012) Methods Enzymol , vol.503 , pp. 255-268
    • Wittrup, K.D.1    Thurber, G.M.2    Schmidt, M.M.3
  • 122
    • 84873084305 scopus 로고    scopus 로고
    • Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
    • Annunziata CM, Kohn EC, Lorusso P et al (2012) Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Invest New Drugs 31:77-84
    • (2012) Invest New Drugs , vol.31 , pp. 77-84
    • Annunziata, C.M.1    Kohn, E.C.2    Lorusso, P.3
  • 123
    • 34247106733 scopus 로고    scopus 로고
    • Phase I/II trial of the prostate-specific membrane antigen (PSMA)-targeted immunoconjugate MLN2704 in patients (pts) with progressive metastatic castration resistant prostate cancer (CRPC
    • Abstract 4500
    • Milowsky M, Galsky M, George M et al (2006) Phase I/II trial of the prostate-specific membrane antigen (PSMA)-targeted immunoconjugate MLN2704 in patients (pts) with progressive metastatic castration resistant prostate cancer (CRPC). J Clin Oncol 24, Abstract 4500
    • (2006) J Clin Oncol , vol.24
    • Milowsky, M.1    Galsky, M.2    George, M.3
  • 124
    • 0037733005 scopus 로고    scopus 로고
    • A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinumsensitive recurrent epithelial ovarian carcinoma
    • Chan SY, Gordon AN, Coleman RE et al (2003) A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinumsensitive recurrent epithelial ovarian carcinoma. Cancer Immunol Immunother CII 52:243-248
    • (2003) Cancer Immunol Immunother CII , vol.52 , pp. 243-248
    • Chan, S.Y.1    Gordon, A.N.2    Coleman, R.E.3
  • 125
    • 0033752234 scopus 로고    scopus 로고
    • Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer
    • Gillespie AM, Broadhead TJ, Chan SY et al (2000) Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer. Ann Oncol J Eur Soc Med Oncol ESMO 11:735-741
    • (2000) Ann Oncol J Eur Soc Med Oncol ESMO , vol.11 , pp. 735-741
    • Gillespie, A.M.1    Broadhead, T.J.2    Chan, S.Y.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.